Abstract
Background: Misoprostol is a synthetic analog of prostaglandin-E1 and it is the most widely used drug for the medical management of incomplete abortion. Acute Coronary Syndrome (ACS) rarely occurs in perimenopausal women, in addition, its presentation is atypical, so the disease is not always recognized.
Case Report: We describe a case of 39-year-old woman with no major underlying cardiovascular risk factors, who developed an episode of ACS following the administration of two doses of misoprostol. After the discontinuation of misoprostol treatment, there was a complete resolution of patient's symptoms. The case draws attention to a rare side effect of a commonly used drug and alerts the clinicians to be cautious in those patients having baseline risk factors which make the patient more susceptible to such serious adverse drug effect.
Keywords: Acute coronary syndrome, misoprostol, prostaglandins, premenopausal women, adverse drug effect, TV-USG.
Current Drug Safety
Title:Misoprostol-induced Acute Coronary Syndrome in a Premenopausal Woman: A Case Report with Literature Review
Volume: 13 Issue: 1
Author(s): Faizan Mazhar*, Jabeen Sultana and Shahzad Akram
Affiliation:
- Department of Basic Medical Sciences, Prince Sultan Military College of Health Sciences, King Fahd Military Medical Complex, Dhahran,Saudi Arabia
Keywords: Acute coronary syndrome, misoprostol, prostaglandins, premenopausal women, adverse drug effect, TV-USG.
Abstract: Background: Misoprostol is a synthetic analog of prostaglandin-E1 and it is the most widely used drug for the medical management of incomplete abortion. Acute Coronary Syndrome (ACS) rarely occurs in perimenopausal women, in addition, its presentation is atypical, so the disease is not always recognized.
Case Report: We describe a case of 39-year-old woman with no major underlying cardiovascular risk factors, who developed an episode of ACS following the administration of two doses of misoprostol. After the discontinuation of misoprostol treatment, there was a complete resolution of patient's symptoms. The case draws attention to a rare side effect of a commonly used drug and alerts the clinicians to be cautious in those patients having baseline risk factors which make the patient more susceptible to such serious adverse drug effect.
Export Options
About this article
Cite this article as:
Mazhar Faizan *, Sultana Jabeen and Akram Shahzad , Misoprostol-induced Acute Coronary Syndrome in a Premenopausal Woman: A Case Report with Literature Review, Current Drug Safety 2018; 13 (1) . https://dx.doi.org/10.2174/1574886312666171122100929
DOI https://dx.doi.org/10.2174/1574886312666171122100929 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Treating and Preventing No Reflow in the Cardiac Catheterization Laboratory
Current Cardiology Reviews Retroviral Vector-mediated Gene Therapy for Metabolic Diseases: An Update
Current Pharmaceutical Design Fondaparinux: Pharmacology and Clinical Experience in Cardiovascular Medicine
Mini-Reviews in Medicinal Chemistry Diagnosis of Vulnerable Plaque and Vulnerable Patient by Coronary Angioscopy and Multi-detector Row Computed Tomography (MDCT) — From Invasive to Non-invasive Plaque Imaging
Vascular Disease Prevention (Discontinued) Biochemical and Pharmacologic Heterogeneity in Low Molecular Weight Heparins. Impact on the Therapeutic Profile
Current Pharmaceutical Design Therapy Against Reperfusion-induced Microvascular Injury
Current Pharmaceutical Design Dealing with the Substance Abuse Epidemic and Infective Endocarditis:Clinical, Immunologic and Pathogenetic Aspects
Current Vascular Pharmacology Ultrasound-Assisted Catheter-Directed Thrombolysis in High-Risk and Intermediate-High-Risk Pulmonary Embolism: A Meta-Analysis
Current Vascular Pharmacology Platelet and Soluble Glycoprotein VI - Novel Applications in Diagnosis and Therapy
Current Drug Targets Low-Molecular-Weight-Heparins: A Review of Literature
Vascular Disease Prevention (Discontinued) Editorial [Hot topic: Antithrombotic Therapy in Cardiovascular and Haematological Diseases: New Perspectives (Executive Editors: Sergio Siragusa, Giuseppe Barbaro and Giovanni Fazio)]
Current Pharmaceutical Design Metabolic Syndrome and Non-Cardiac Vascular Diseases: An Update from Human Studies
Current Pharmaceutical Design Biomarker Assays for Personalised Stroke Risk Assessment in Atrial Fibrillation
Cardiovascular & Hematological Disorders-Drug Targets Patent Selections:
Recent Patents on Biomarkers Extracellular Proteases as Targets for Drug Development
Current Protein & Peptide Science Role of Diagnostic Ultrasound in Patient Selection for Stroke Intervention
Recent Patents on CNS Drug Discovery (Discontinued) Inhalation Gases or Gaseous Mediators As Neuroprotectants for Cerebral Ischaemia
Current Drug Targets Primary Prevention of Ischaemic Stroke in Atrial Fibrillation: New Oral Anticoagulant Drugs for all?
Current Vascular Pharmacology Mechanisms of Cardioprotection of Halogenated Agents During Extracorporeal Circulation in Cardiac Surgery
Current Vascular Pharmacology Thromboembolism with Immunomodulatory Agents in the Treatment of Multiple Myeloma
Cardiovascular & Hematological Agents in Medicinal Chemistry